GlassScriptPhysician profile
Iftikhar Kullo
NPI 1104890581
$11,214.87
in general payments reported to CMS, 2019-2025
6 companies · $1,647 in 2025
The $1,647 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,512 · 2020: $750 · 2021: $2,250 · 2023: $1,500 · 2024: $1,556 · 2025: $1,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,000 · Consulting Fee: $1,500 · Food and Beverage: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,000.00 |
| Consulting Fee | $1,500.00 |
| Food and Beverage | $202.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fukuda Denshi Co., LTD. | $5,396.72 | 2021-2025 | Vs-2000 |
| Roche Diabetes Care Gmbh | $3,500.00 | 2019 | |
| Kaneka Medical America LLC | $1,500.00 | 2021 | |
| Fukuda Denshi Co., LTD. | $750.00 | 2020 | |
| Amgen INC. | $55.70 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iftikhar Kullo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.